We have observed
9 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 17, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
BICYCLIC PYRIMIDONE COMPOUNDS
2,3-DIHYDROIMIDAZO[1,2-C]PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA INHIBITORS
NOVEL CRYSTAL FORM
BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2
2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS
PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2
HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE